In collaboration with neurologists, endocrinologists, other physicians, and basic scientists, the Columbia Neuropathy Research Center is committed to basic and human research designed to improve our understanding and effective treatment of peripheral and autonomic neuropathies of all types.
The CNRC is funded exclusively by donor support and research grants.
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ACE-083 IN PATIENTS WITH CHARCOT-MAIE-TOOTH DISEASE TYPES 1 AND X
Click here for more information
TOPIRAMATE AS A DISEASE MODIFYING THERAPY FOR CRYPTOGENIC SENSORY PERIPHERAL NEUROPATHY IN METABOLIC SYNDROME (CSPN) (TOPIRAMATE FOR CRYPTOGENIC SENSORY PERIPHERAL NEUROPATHY (TOPCSPN))
This is a Phase II study to learn if the drug topiramate slows the progression of Cryptogenic Sensory Peripheral Neuropathy (CSPN), (also known as “idiopathic neuropathy” or neuropathy of an unknown cause), and improves quality of life. As part of this study, we will use a number of assessments and questionnaires to determine if topiramate improves symptoms of CSPN. There is a one in two (or 50%) chance of receiving the study drug or placebo pill.
For more information and to see if you qualify, please call:
The Columbia Neuropathy Research Center
The Neurological Institute
710 West 168th Street, 2nd floor
New York, NY 10032